Mode
Text Size
Log in / Sign up
N/A N=85 Randomized Triple-blind Treatment

Comprehensive Magnetic Resonance of Peripheral Arterial Disease

Peripheral Artery Disease

Enrolled (actual)
85
Serious AEs
0.0%
Results posted
Feb 2012
Primary outcome: Primary: Plaque Volume — 10.5; 10.5; 10.8 cm^3 — p=0.32

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Simvastatin (Drug); Ezetimibe (Drug); Simvastatin/Ezetimibe (Drug)
Age
Adult, Older Adult · 30+ yrs
Sex
All
Sponsor
University of Virginia
Primary completion
Oct 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Plaque Volume
10.5; 10.5; 10.8 0.32
PRIMARY
Perfusion Index
0.34; 0.37; 0.54 0.71
PRIMARY
Phosphocreatine Recovery Time Constant - the Time it Takes for Phosphocreatine Levels to Recover to Plateau.
84; 73; 74 0.67
SECONDARY
Low Density Lipoprotein Cholesterol
83; 68; 77 0.31
SECONDARY
Total Cholesterol
152; 136; 144 0.37
SECONDARY
High Density Lipoprotein Cholesterol
44; 46; 43 0.78
SECONDARY
Triglycerides
171; 119; 152 0.68
SECONDARY
Magnetic Resonance Angiographic Index
0.71; 1.32; 0.63 <0.05 sig
SECONDARY
Log Treadmill Exercise Time
5.92; 5.79; 5.78 =0.67
SECONDARY
6-minute Walk Distance
1078; 1038; 1099 0.77
SECONDARY
V02 - Maximal Oxygen Consumption
14.8; 12.1; 12.3 0.85

Summary

The purpose of this study is to develop new ways of imaging fatty blockages in the leg arteries to improve upon techniques used now and to develop new ways of understanding how new treatments may affect the disease.

Eligibility Criteria

Inclusion Criteria

Patients age 30-85 referred to the vascular imaging laboratory with documented evidence of peripheral arterial disease (0.4 85

GFR less than 45mL/min based on a serum creatinine drawn within 90 days of the MRI:

Pregnancy Contraindications to a magnetic resonance examination

  • Intracranial clips
  • Implantable pacemaker and defibrillator
  • Cochlear or intraocular implants
  • Claustrophobia
  • Any metallic implant not listed as magnetic resonance compatible in Shellock F.G ---Pocket Guide to Magnetic Resonance Procedures and Metallic Objects, Update 2000. Lippincott, Williams and Wilkins
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00587678). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search